1. Home
  2. MBIO vs MEHA Comparison

MBIO vs MEHA Comparison

Compare MBIO & MEHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBIO
  • MEHA
  • Stock Information
  • Founded
  • MBIO 2015
  • MEHA 2020
  • Country
  • MBIO United States
  • MEHA United States
  • Employees
  • MBIO N/A
  • MEHA N/A
  • Industry
  • MBIO Biotechnology: Pharmaceutical Preparations
  • MEHA Medicinal Chemicals and Botanical Products
  • Sector
  • MBIO Health Care
  • MEHA Health Care
  • Exchange
  • MBIO Nasdaq
  • MEHA Nasdaq
  • Market Cap
  • MBIO 4.7M
  • MEHA 4.8M
  • IPO Year
  • MBIO N/A
  • MEHA N/A
  • Fundamental
  • Price
  • MBIO $1.22
  • MEHA $0.42
  • Analyst Decision
  • MBIO
  • MEHA
  • Analyst Count
  • MBIO 0
  • MEHA 0
  • Target Price
  • MBIO N/A
  • MEHA N/A
  • AVG Volume (30 Days)
  • MBIO 81.7K
  • MEHA 4.2M
  • Earning Date
  • MBIO 11-07-2025
  • MEHA 01-01-0001
  • Dividend Yield
  • MBIO N/A
  • MEHA N/A
  • EPS Growth
  • MBIO N/A
  • MEHA N/A
  • EPS
  • MBIO N/A
  • MEHA N/A
  • Revenue
  • MBIO N/A
  • MEHA $6,498,798.00
  • Revenue This Year
  • MBIO N/A
  • MEHA N/A
  • Revenue Next Year
  • MBIO N/A
  • MEHA N/A
  • P/E Ratio
  • MBIO N/A
  • MEHA N/A
  • Revenue Growth
  • MBIO N/A
  • MEHA N/A
  • 52 Week Low
  • MBIO $0.89
  • MEHA $0.34
  • 52 Week High
  • MBIO $21.95
  • MEHA $8.00
  • Technical
  • Relative Strength Index (RSI)
  • MBIO 35.63
  • MEHA N/A
  • Support Level
  • MBIO $1.14
  • MEHA N/A
  • Resistance Level
  • MBIO $1.27
  • MEHA N/A
  • Average True Range (ATR)
  • MBIO 0.09
  • MEHA 0.00
  • MACD
  • MBIO -0.01
  • MEHA 0.00
  • Stochastic Oscillator
  • MBIO 20.23
  • MEHA 0.00

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: